<DOC>
	<DOCNO>NCT00329550</DOCNO>
	<brief_summary>This multi-centre , open-label extension study subject show clinical response induction therapy treatment subject active Crohn 's disease double-blind main study C87037 ( NCT00291668 ) .</brief_summary>
	<brief_title>Maintenance Study Certolizumab Pegol ( CZP ) Crohn 's Disease</brief_title>
	<detailed_description>In double-blind main study subject dose Weeks 0 , 2 4 , primary outcome , clinical response , assess Week 6 . Subjects show clinical response Week 6 eligible enter open-label extension study . The first visit extension study 2 week Week 6 , i.e. , Week 8 . Subjects extension study dose Weeks 8 , 12 , 16 , 20 24 , primary outcome , clinical response , assess Week 26 . All week number quote relative start double-blind main study .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subjects participate main doubleblind induction study C87037 ( NCT00291668 ) show clinical efficacy Subjects experience aggravation Crohn 's disease main doubleblind induction study C87037 ( NCT00291668 ) require treatment change</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Certolizumab pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>CZP</keyword>
</DOC>